Newly Launched Trastuzumab Biosimilars Trigger Price Cuts In India
This article was originally published in PharmAsia News
Executive Summary
Even as litigation shadows opportunities for trastuzumab biosimilars in India, dealers noted that discounted prices are being offered across the board. The four-way rivalry with Biocon and Mylan on one side and Roche and Emcure on the other, has already intensified market competition, experts say.